1.0nukliD® – Radiopharmacy Cluster Dresdenhttps://nuklid.network/ensysadminhttps://nuklid.network/en/news/author/sysadminABX-CRO - nukliD® – Radiopharmacy Cluster Dresdenrich600338<blockquote class="wp-embedded-content" data-secret="LRYzpWpqk2"><a href="https://nuklid.network/en/partner/abx-cro">ABX-CRO</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://nuklid.network/en/partner/abx-cro/embed#?secret=LRYzpWpqk2" width="600" height="338" title="“ABX-CRO” — nukliD® – Radiopharmacy Cluster Dresden" data-secret="LRYzpWpqk2" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://nuklid.network/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://nuklid.network/wp-content/uploads/2025/01/ABX_CRO_Logo.png1280735ABX-CRO has more than 20 years of unique experience in the development of therapeutic radiopharmaceuticals and molecular imaging agents. Our experience from more than 50 phase 0-3 radiopharmaceutical studies including alpha, beta, auger, PET and SPECT radionuclides labeled with pharmacophores ranging from small molecules, peptides and monoclonals to medical devices is unmatched in the CRO industry. Our specialized Image Core ... Read More